Company intelligence / Profile preview

Sinovac Research and Development

Beijing, Beijing, China

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Sinovac is globally recognized for its COVID-19 vaccine, CoronaVac, an inactivated vaccine that received WHO Emergency Use Listing. The company has a strong commercial portfolio of vaccines for Hepatitis A (Healive), HFMD (Inlive), and seasonal influenza. Recent R&D efforts focus on mRNA-based vaccines for COVID-19 variants and combined vaccines.

Therapeutic areas: Infectious Diseases
Modalities: VaccinemRNA-based drugsMonoclonal antibodyRecombinant proteinBiologic
Industry: Pharma

Partnerships

Butantan InstituteBio FarmaGlaxoSmithKlineVABIOTECH

Beyond the preview

Go deeper on Sinovac Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinovac Research and Development.

Explore the full profile